scholarly journals Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy

Oncotarget ◽  
2017 ◽  
Vol 8 (69) ◽  
pp. 113531-113542 ◽  
Author(s):  
Annelot G.J. van Rossum ◽  
Marleen Kok ◽  
Danielle McCool ◽  
Mark Opdam ◽  
Nienke C. Miltenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Independent Replication ◽  
Dose Dense

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

2017 ◽  
Vol 71 ◽  
pp. 34-42 ◽  
Author(s):  
Matteo Lambertini ◽  
Marcello Ceppi ◽  
Francesco Cognetti ◽  
Giovanna Cavazzini ◽  
Michele De Laurentiis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Dose Dense ◽  
Phase Iii Studies

scholarly journals The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy

2016 ◽  
Vol 27 ◽  
pp. iv64
Author(s):  
C. Fontanella ◽  
L. Del Mastro ◽  
S. De Placido ◽  
M. De Laurentiis ◽  
C. Boni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Dose Dense

scholarly journals Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-6
Author(s):  
Hamid Reza Mirzaei ◽  
Fatemeh Nasrollahi ◽  
Ladan Mohammadi Yeganeh ◽  
Sepideh Jafari Naeini ◽  
Pegah Bikdeli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Weekly Paclitaxel ◽  
Hematologic Toxicity ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Grade 3 ◽  
Dose Dense ◽  
Positive Breast Cancer

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined. Objectives. The feasibility of dose-dense epirubicin in combination with cyclophosphamide (EC) followed by weekly paclitaxel as adjuvant chemotherapy in node-positive breast cancer patients was investigated. Methods. All patients were treated with epirubicin (100 mg/m2) and cyclophosphamide (600 mg/m2) every two weeks for four cycles with daily Pegfilgrastim (G-CSF) that was administered 3–10 days after each cycle of epirubicin and cyclophosphamide infusion which followed by (80 mg/m2) paclitaxel for twelve consecutive weeks. Results. Sixty consecutive patients were analyzed, of whom 57 patients (95%) completed the regimen and no case of toxicity-related death was observed. Grade 3/4 hematologic toxicity was uncommon and the most common grade 3/4 nonhematological adverse event was neuropathy disorders. Conclusions. Dose-dense epirubicin and cyclophosphamide followed by weekly paclitaxel with G-CSF support is a well-tolerated and feasible regimen in node-positive breast cancer patients without serious complications.

Sign in / Sign up

Export Citation Format

Share Document